MDMA-assisted psychotherapy with adolescents suffering from PTSD: Do or don’t? a qualitative study with youth, parents, and clinicians

Post-traumatic stress disorder (PTSD) in adolescents is a significant public health problem that can cause persistent symptoms across re-experiencing, avoidance, negative cognitions/mood, and hyperarousal, and it carries substantial health-care costs. Existing evidence-based psychological treatments such as trauma-focused cognitive behavioural therapy (TF-CBT) and Eye Movement Desensitization and Reprocessing (EMDR) benefit many young people, but dropout rates (13–36%) and a non-response subgroup (around 20%) leave important unmet needs. Complex PTSD (cPTSD), characterised by severe affect regulation problems, persistent negative self-concept, and interpersonal difficulties, predicts poorer response to conventional therapies, and pharmacotherapy (SSRIs) has not shown clear superiority to placebo in adolescents. Against this background, MDMA-assisted psychotherapy (MDMA-AP) has emerged as a promising, cost-effective adjunct to psychotherapy for treatment-resistant PTSD in adults; recent Phase II and Phase III trials reported safety and substantial symptom reduction. Van Vugt and colleagues note that no empirical research has yet examined MDMA-AP in adolescents. To address this gap they conducted a qualitative study to explore how three stakeholder groups—adolescents with trauma therapy experience, parents of traumatised children, and clinicians specialising in childhood trauma—perceive the feasibility, potential risks and benefits, and necessary precautions prior to any adolescent MDMA-AP clinical trials. The study aimed to answer three questions: Do participants consider MDMA a feasible option for adolescent PTSD, what risks or benefits do they foresee, and what precautions should precede a potential trial?

This qualitative study used online focus groups conducted in October 2021 with three purposively recruited samples: adolescents who had received trauma therapy (N = 9; ages 16–25, four women, four men, one non-binary), parents of traumatised children (N = 4; three mothers, one father), and clinicians specialising in childhood trauma (N = 6; four female, two male). Recruitment employed convenience sampling via a youth care institution, an innovation network, flyers sent to local psychology practices, and social media. Ethical approval was obtained and all participants gave informed consent. Focus groups lasted 60–90 minutes, were facilitated by two researchers with a note-taker present, and began by eliciting participants' spontaneous associations with MDMA. A standardised video clip explaining MDMA-AP (clinician explanation plus a veteran’s testimonial) was then shown, followed by additional verbal information and further discussion. Sessions were audio-recorded, transcribed verbatim, anonymised, and then deleted. An intake call prior to each focus group collected background details and screened participants. Data analysis followed a grounded theory–informed approach combining deductive and inductive coding. Van Vugt (AvV) coded the first transcript in ATLAS.ti using a pre-specified deductive coding tree aligned with the research questions, then added inductive subcodes that emerged. The coding framework comprised four main categories: (1) perception/associations with MDMA, (2) initial ideas on MDMA-AP, (3) risks and benefits, and (4) implementation considerations; each was split into relevant subcodes (e.g. positive/negative, risks/benefits, what to do/what not to do). LvD reviewed the codebook and coding was applied to the remaining transcripts with iterative discussion among coders. The authors note a limitation intrinsic to focus groups: they could not reliably count how many individuals endorsed a view because participants often refrained from repeating previously stated opinions.

Four core themes structured the findings: perceptions/associations with MDMA, initial reactions to MDMA-AP after viewing explanatory material, perceived risks and benefits, and practical considerations for implementation. Across these themes the three stakeholder groups showed both shared and divergent views. Perception and associations with MDMA: Initial spontaneous associations were predominantly negative, with MDMA commonly labelled a party drug. Among adolescents, the four who had prior recreational use described both positive (increased sociability, sense of belonging) and negative experiences; one adolescent who had not used MDMA nonetheless recognised the reported emotional effects. Parents’ first reactions urged avoidance because of the party-drug image, although some also acknowledged that MDMA can induce positive feelings. Clinicians, none of whom had personal MDMA experience, associated the drug with oxytocin-like interpersonal effects but also with party use, basing impressions on second-hand reports. Initial ideas on MDMA-AP: After the standardised video and verbal explanation, most adolescents (all but one) expressed willingness to try MDMA-AP, emphasising curiosity about accessing deeper emotions and parts of experience they could not otherwise reach. The dissenting adolescent cited fears around addiction. Parents remained surprised by practical aspects such as eight-hour therapy sessions and voiced concerns about guiding an adolescent through a prolonged experience, yet all parents said they would consider MDMA-AP for themselves or their children if it proved helpful. Clinicians raised practical and safety reservations—illegal market composition (addressed by researchers with the point that clinical MDMA is produced legally), ‘‘the day after’’ low mood, and potential for adolescents to view MDMA as a self-medication—but several clinicians also saw MDMA-AP as a promising adjunct for treatment-resistant cases. Potential risks and benefits: Participants across groups converged on the perceived therapeutic benefit that MDMA creates a different mental state in which negative emotions are attenuated, facilitating access to traumatic material and strengthening therapeutic alliance. Adolescents additionally worried about possible effects on brain development given ongoing neurodevelopment in adolescence and asked whether adult data generalise to younger people. The ‘‘day after’’ low mood and addiction risk were recurrent concerns among adolescents and parents; clinicians worried especially about long-term unknowns and logistical demands of long sessions (therapist fatigue, need for multiple trained therapists, funding). Clinicians also highlighted MDMA-AP’s potential to shorten treatment duration and to serve as a ‘‘last step’’ before more restrictive care. Considerations for implementing MDMA-AP: Participants emphasised tailored protocols and integration with standard therapy rather than replacing it. Adolescents preferred MDMA-AP to be offered alongside their existing therapeutic relationship, and many wanted the option of overnight stay to be optional (not mandatory) because unfamiliar environments can be triggering. Parents prioritised predictability, thorough psychoeducation for adolescents and families, a comfortable room resembling a living room rather than a clinic, and pre-existing trust between therapist and client; they also noted that chaotic home environments may undermine therapy. Clinicians debated appropriate minimum age and decision-making capacity—citing the four competencies for informed decisions (expressing a choice, understanding, reasoning, appreciation)—and recommended small-scale, long-term studies to assess cognitive and clinical outcomes. Across groups the stigma associated with ‘‘party drug’’ terminology was raised, with some suggesting renaming the treatment. Numerically, the sample was N = 19 overall (adolescents N = 9, parents N = 4, clinicians N = 6), and the authors report that after receiving standardised information all but one participant became supportive of exploring MDMA-AP for adolescents.

Van Vugt and colleagues interpret the findings as showing that initial negative attitudes towards MDMA can shift to conditional support for adolescent MDMA-AP when stakeholders receive standardised information about the therapeutic model. Participants across groups identified the primary therapeutic advantage as an MDMA-induced ‘‘different state of mind’’ that can attenuate negative affect and permit deeper engagement with traumatic memory; clinicians additionally emphasised potential gains in therapeutic alliance and shorter treatment courses. Major concerns that remained central to participants were possible impacts on adolescent cognitive development, addiction risk, the need for a safe and confidential setting, and comprehensive psychoeducation for patients and families. The study team positions these results relative to prior research by noting that earlier survey-based studies found clinicians more pessimistic about psychedelic-assisted therapies; unlike surveys, the focus-group format allowed participants to ask questions and to discuss the information together, which appeared to shift views. The authors recommend careful screening for decision-making capacity using the four competencies and stress that age per se was not settled by participants—views varied and no consensus on a minimum age emerged. Acknowledged limitations include the small parent focus group (N = 4) with two participants being a couple, potential interviewer or social-desirability bias inherent to focus groups, and possible sampling bias because participants self-selected and might have pre-existing interest in psychedelics. Strengths cited are the use of standardised topic guides across groups, the same facilitator for all focus groups ensuring comparability, and a sample of adolescents with lived trauma-treatment experience, which is a difficult population to recruit for group discussions. On the basis of their findings the authors conclude that stakeholders may be generally supportive of testing MDMA-AP for adolescents provided adequate information, careful precautions, and attention to key factors: ensuring participants can make well-considered decisions, creating individually tailored safe settings with robust after-care (a ‘‘soft landing’’), integrating MDMA-AP with other therapies (ideally early in the treatment course), and carefully considering contraindications such as comorbidities. They emphasise the need for further short- and long-term research to address the outstanding concerns about developmental impact and long-term outcomes.